SALT LAKE CITY--In a collaboration that Myriad Genetics here values at $51 million, German pharmaceutical company Schering will use Myriad's protein-to-protein interaction technology ProNet to study biochemical pathways of major diseases. In North America, Myriad will have an option to copromote in all new therapeutic products and receive 50 percent of profits from sales of drugs discovered using the technology. Myriad said it will collaborate with Schering scientists to identify drug targets using ProNet to reveal the cascade of protein interactions that lead to major human diseases.
Schering Will Utilize Myriad's ProNet Product
Nov 21, 1998